PROCEPT BioRobotics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

PROCEPT BioRobotics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.2%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.2%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

Oct 31

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Sep 12

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Aug 27

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

Aug 25

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

Aug 04

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PRCT şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PRCT şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

PROCEPT BioRobotics Piyasaya Karşı Temettü Getirisi

PRCT temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PRCT)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (PRCT) (3 yıla kadar)	0%

Önemli Temettü: PRCT şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PRCT şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PRCT şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PRCT herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

PROCEPT BioRobotics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Price Target To US$102

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $174.999916 million.

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation has filed a Follow-on Equity Offering in the amount of $175 million.

PROCEPT BioRobotics Corporation to Report Q3, 2024 Results on Oct 28, 2024

PROCEPT BioRobotics Received U.S. FDA Approval to Initiate Pivotal Randomized Clinical Study for Prostate Cancer

Procept BioRobotics: New Hydros Aquablation System To Fuel Next Leg Of Growth

Procept BioRobotics: Risk Capital Unlock With FDA Hydros Approval

Investors Appear Satisfied With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Prospects As Shares Rocket 28%

PROCEPT BioRobotics Announces FDA Clearance of the HYDROS™ Robotic System, the Next-Generation, AI-Powered Platform for Aquablation® Therapy

Here's What Analysts Are Forecasting For PROCEPT BioRobotics Corporation (NASDAQ:PRCT) After Its Second-Quarter Results

PROCEPT BioRobotics Corporation Revises Revenue Guidance for Full Year 2024

PROCEPT BioRobotics Corporation to Report Q2, 2024 Results on Aug 01, 2024

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock

Executive VP & CFO recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

No longer forecast to breakeven

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

PROCEPT BioRobotics Corporation to Report Q4, 2022 Results on Feb 28, 2023

Now 22% undervalued

High number of new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

PROCEPT BioRobotics Corporation Projects Earnings Guidance for the Full Year 2022

Now 20% undervalued

PROCEPT BioRobotics Corporation to Report Q3, 2022 Results on Nov 03, 2022

Procept Biorobotics announces $52M debt refinancing

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Procept BioRobotics Has Resources To Ramp Up Commercialization

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.43 loss per share (vs US$2.61 loss in 2Q 2021)